Safety and Effectiveness of Mirabegron for Children and Adolescents with Refractory Idiopathic Overactive Bladder for Improving Urinary Symptoms: a Systematic Review

Overview

Journal Cent European J Urol

Specialty Urology

Date 2024 Sep 30

PMID 39345308

Authors

Daniela Franco-Buenaventura

Herney Andres Garcia-Perdomo

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of this study was to determine the safety and effectiveness of mirabegron in children with refractory overactive bladder (OAB) for improving urinary symptoms.

Material And Methods: We conducted a search strategy in MEDLINE (OVID), EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), and LILACS from inception to September 2023. We performed a systematic review of studies evaluating the effectiveness of improving urinary symptoms and the safety of mirabegron at any dose in children and adolescents with idiopathic refractory OAB. We searched the interception to September 2023. The risk of bias was assessed using the Cochrane risk of bias tool for clinical trials and the MINORS tool for non-randomized studies.

Results: We included three studies in the analysis. All of them included children and adolescents receiving mirabegron as monotherapy at different doses. Also, none of them reported a control group. Improvement and safety rates were high in every study in objective and subjective measurements. Compliance was also high in all studies. Most of the evaluated items had a low risk of bias within and across studies.

Conclusions: Mirabegron as monotherapy appears to be a safe and effective alternative for children with refractory idiopathic OAB or those who are intolerant to antimuscarinic therapy.

References

Chung J, Lee S, Kang D, Kwon D, Kim K, Kim S . Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study. Urology. 2008; 73(1):63-7. DOI: 10.1016/j.urology.2008.06.063. View

Bartoli S, Aguzzi G, Tarricone R . Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2009; 75(3):491-500. DOI: 10.1016/j.urology.2009.07.1325. View

Soliman M, El-Abd S, El-Gamal O, Abdel Raheem A, Abou-Ramadan A, El-Abd A . Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial. Urol Int. 2021; 105(11-12):1011-1017. DOI: 10.1159/000515992. View

Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T . Nocturnal enuresis and overactive bladder in children: an epidemiological study. Int J Urol. 2006; 13(1):36-41. DOI: 10.1111/j.1442-2042.2006.01217.x. View

Fryer S, Nicoara C, Dobson E, Griffiths M, McAndrew H, Kenny S . Effectiveness and tolerability of mirabegron in children with overactive bladder: A retrospective pilot study. J Pediatr Surg. 2019; 55(2):316-318. DOI: 10.1016/j.jpedsurg.2019.10.044. View

Franco I . Overactive bladder in children. Nat Rev Urol. 2016; 13(9):520-32. DOI: 10.1038/nrurol.2016.152. View

Rittig S, Baka-Ostrowska M, Tondel C, Walle J, Kjaeer B, Passier P . The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. J Pediatr Urol. 2019; 16(1):31.e1-31.e10. DOI: 10.1016/j.jpurol.2019.10.009. View

Landgraf J, Abidari J, Cilento Jr B, Cooper C, Schulman S, Ortenberg J . Coping, commitment, and attitude: quantifying the everyday burden of enuresis on children and their families. Pediatrics. 2004; 113(2):334-44. DOI: 10.1542/peds.113.2.334. View

Morin F, Blais A, Nadeau G, Moore K, Genois L, Bolduc S . Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol. 2016; 197(4):1158-1163. DOI: 10.1016/j.juro.2016.11.101. View

10.

Oefelein M . Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf. 2011; 34(9):733-54. DOI: 10.2165/11592790-000000000-00000. View

11.

Park J, Lee Y, Lee C, Kim S, Kim S, Han S . Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2018; 37(8):1665-1670. DOI: 10.1007/s00345-018-2576-0. View

12.

Blais A, Bergeron M, Nadeau G, Ramsay S, Bolduc S . Anticholinergic use in children: Persistence and patterns of therapy. Can Urol Assoc J. 2016; 10(3-4):137-40. PMC: 4839996. DOI: 10.5489/cuaj.3527. View

13.

Blais A, Nadeau G, Moore K, Genois L, Bolduc S . Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Eur Urol. 2016; 70(1):9-13. DOI: 10.1016/j.eururo.2016.02.007. View

14.

Melling C, Goyal A . Current pharmacological management of idiopathic overactive bladder in children in the UK: a national survey of practice. J Pediatr Urol. 2019; 16(1):37.e1-37.e8. DOI: 10.1016/j.jpurol.2019.10.013. View